10 Hrs
Source:
الخليج
Experimental therapy for small cell lung cancer
An international clinical study has demonstrated the effectiveness of an experimental drug combination of pometameg and eltafaparte-drozontican in treating small cell lung cancer, recording an initial response rate of 70.4% and treatment flexibility across different stages, with disease control reaching 93%. Approximately 193 patients participated in the study, with promising results that combine efficacy and safety, especially in patients who had received prior treatment. The findings suggest that this combination represents a promising development in the treatment of small cell lung cancer.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)